[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

FR2452287A1 - Substance activant le plasminogene, sa preparation et medicament renfermant cette substance - Google Patents

Substance activant le plasminogene, sa preparation et medicament renfermant cette substance

Info

Publication number
FR2452287A1
FR2452287A1 FR8006957A FR8006957A FR2452287A1 FR 2452287 A1 FR2452287 A1 FR 2452287A1 FR 8006957 A FR8006957 A FR 8006957A FR 8006957 A FR8006957 A FR 8006957A FR 2452287 A1 FR2452287 A1 FR 2452287A1
Authority
FR
France
Prior art keywords
substance
effect
plasminogen
mca
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR8006957A
Other languages
English (en)
Other versions
FR2452287B1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tobishi Pharmaceutical Co Ltd
Original Assignee
Tobishi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tobishi Pharmaceutical Co Ltd filed Critical Tobishi Pharmaceutical Co Ltd
Publication of FR2452287A1 publication Critical patent/FR2452287A1/fr
Application granted granted Critical
Publication of FR2452287B1 publication Critical patent/FR2452287B1/fr
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA SUBSTANCE ACTIVANT LE PLASMINOGENE EST EXTRAITE DE LA BILE DE PORC. CETTE SUBSTANCE PRESENTE UNE MASSE MOLECULAIRE DE 8000010000, UN POINT ISOELECTRIQUE DE 7,1, UN SPECTRE D'ABSORPTION ULTRAVIOLET PRESENTANT UN PIC (LMAX) A UNE LONGUEUR D'ONDE D'ENVIRON 278NM, UNE ACTIVITE FIBRINOLYTIQUE TELLE QU'UNE PLAQUE DE FIBRINE ETALON A LAQUELLE ON A AJOUTE DU CA EST DEGRADEE MAIS QU'UNE PLAQUE DE FIBRINE CHAUFFEE N'EST PAS DEGRADEE, UNE STABILITE THERMIQUE TELLE QU'UN CHAUFFAGE A UNE TEMPERATURE DE 80C PENDANT DIX MINUTES PROVOQUE UNE DIMINUTION DE L'EFFET D'ACTIVATION DU PLASMINOGENE CORRESPONDANT A 50 DE L'EFFET INITIAL ET QU'UN CHAUFFAGE A UNE TEMPERATURE DE 60C PENDANT 30MINUTES PROVOQUE UNE DIMINUTION DE L'EFFET D'ACTIVATION DU PLASMINOGENE CORRESPONDANT A 30-40 DE L'EFFET INITIAL, UNE SOLUBILITE DANS LE SERUM ET UNE INSOLUBILITE DANS DES SOLVANTS ORGANIQUES SOLUBLES DANS L'EAU; ET UN EFFET DE DEGRADATION DES SUBSTRATS SYNTHETIQUES TEL QUE LA GLUTARYL-GLY-ARG-MCA ET LA PRO-PHE-ARG-MCA NE SONT QUE FAIBLEMENT HYDROLYSEES. UTILISATION : MEDICAMENT CONTRE LA THROMBOSE.
FR8006957A 1979-03-30 1980-03-28 Substance activant le plasminogene, sa preparation et medicament renfermant cette substance Granted FR2452287A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP3698079A JPS55130918A (en) 1979-03-30 1979-03-30 Plasminogen-activating agent and its preparation

Publications (2)

Publication Number Publication Date
FR2452287A1 true FR2452287A1 (fr) 1980-10-24
FR2452287B1 FR2452287B1 (fr) 1983-05-06

Family

ID=12484891

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8006957A Granted FR2452287A1 (fr) 1979-03-30 1980-03-28 Substance activant le plasminogene, sa preparation et medicament renfermant cette substance

Country Status (7)

Country Link
US (1) US4265881A (fr)
JP (1) JPS55130918A (fr)
CA (1) CA1139661A (fr)
CH (1) CH645406A5 (fr)
DE (1) DE3011956A1 (fr)
FR (1) FR2452287A1 (fr)
GB (1) GB2045257B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2507339B2 (ja) * 1986-08-11 1996-06-12 三井東圧化学株式会社 粗ｔＰＡの精製方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086140A (en) * 1972-04-05 1978-04-25 John Burnham King Process for isolating fibrinolytic substances

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086140A (en) * 1972-04-05 1978-04-25 John Burnham King Process for isolating fibrinolytic substances

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CA1969 *
CA1975 *

Also Published As

Publication number Publication date
DE3011956A1 (de) 1980-11-20
GB2045257A (en) 1980-10-29
GB2045257B (en) 1983-01-26
CH645406A5 (de) 1984-09-28
CA1139661A (fr) 1983-01-18
FR2452287B1 (fr) 1983-05-06
JPS55130918A (en) 1980-10-11
US4265881A (en) 1981-05-05

Similar Documents

Publication Publication Date Title
US5603956A (en) Cross-linked enzymatically controlled drug release
WO1997041843A3 (fr) Chewing-gum medicamenteux possedant un gout agreable et contenant un complexe d'insertion
DK12285A (da) Fremgangsmaade til udnyttelse af tobaksstoev
DE69012985D1 (de) Verkapselung von mischgetrockneter sucralose mit polyvinylacetat zur verwendung in kaugummi.
KR890009287A (ko) 물리적 안정성이 증진된 츄잉껌 조성물
FI905937A0 (fi) Behandling av fruktmaterial.
ES2085273T3 (es) Procedimiento para preparar una composicion detergente granular de alta densidad aparente.
NO176786C (no) Fremgangsmåte for fremstilling av lysfölsomme hematoporfyrinforbindelser
AU4965497A (en) Tablet composition
ES498766A0 (es) Procedimiento para la preparacion de acidos carboxilicos
IS1565B (is) Aðferð við framleiðslu á N1-súbstitúeruðum bensimidasólafleiðum til að nota við lækningar
Kenchington Chemical modification of the side chains of gelatin
NO974693L (no) Farmasöytisk preparat inneholdende N-klorfenylkarbamater, N-klorfenyltiokarbamater og N-fosfonoglycin-derivater for å inhibere vekst av cancer og virus i pattedyr
EP0651634B1 (fr) Materiau polyhydroxylique reticule pour liberation de medicaments regulee enzymatiquement
FR2452287A1 (fr) Substance activant le plasminogene, sa preparation et medicament renfermant cette substance
ES8703277A1 (es) Un procedimiento para cargar un polimero insoluble en agua yesponjable en agua con acetato de metilhidroxiprogesterona
DE69824853D1 (de) Zusammensetzungen und gegenstände zur verminderung der auswirkung von entzündungen
BG96200A (bg) Гранулат,съдържащ натриев 2-меркаптоетансулфонат като активно вещество и метод за получаването му
DK72989D0 (da) Fremgangsmaade til fremstilling af en fast komposition af lactulose
RU94044362A (ru) Способ обесцвечивания кератиновых волокон
NO913009D0 (no) Fremgangsmaate for fremstilling av anilinderivater.
Gusev et al. Motility of the N-terminal tail of phosphorylase b as revealed by crosslinking
NO863448D0 (no) Fremgangsmaate ved fremstilling av oculoselektive beta-blokker.
Lantz The effect of intensity of the preexposed stimulus on subsequent conditioning
ES8303288A1 (es) Procedimiento de obtencion de la n-(trans-4-hidroxi-ciclo- hexil-)-(2-amino-3,5-dibromo)bencilamina y sus sales farma- ceuticamente aceptables.

Legal Events

Date Code Title Description
ST Notification of lapse